小核酸跻身第三大药物类别，中国药企已斩获超60亿美元BD大单，重点公司已圈出

Group 1: Natural Gas Development in the Middle East - The acceleration of natural gas development in the Middle East is driven by the energy transition and increasing power generation demand, creating a strategic window for development [3][5] - Two leading equipment companies have secured significant orders in the Middle East, with one company obtaining a $1.5 billion order, accounting for 10% of the market share, and another company expected to double its orders over three years [2][3] - The expansion of the entire natural gas extraction, processing, liquefaction, and transportation chain is anticipated to significantly boost engineering construction and high-end equipment demand in the region [3] Group 2: Small Nucleic Acid Drugs in the Pharmaceutical Industry - Small nucleic acid drugs are emerging as the third major category of pharmaceuticals, with Chinese pharmaceutical companies securing over $6 billion in business development (BD) deals [7][8] - The market for small nucleic acid drugs is expected to grow, particularly in chronic disease treatment, with a focus on hepatitis B and cardiovascular diseases [7][8] - The increasing frequency of large BD deals highlights the potential of early-stage chronic disease pipelines in the pharmaceutical sector [8]